These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36057890)

  • 21. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
    Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
    J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data.
    Halligan SJ; Grainge MJ; Martinez-Calle N; Fox CP; Bishton MJ
    Br J Haematol; 2022 Feb; 196(4):932-938. PubMed ID: 34664265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
    Gandolfi L; Pellegrini C; Casadei B; Stefoni V; Broccoli A; Tonialini L; Morigi A; Argnani L; Zinzani PL
    Oncologist; 2016 Dec; 21(12):1436-1441. PubMed ID: 27486201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
    Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
    Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
    Svoboda J; Bair SM; Landsburg DJ; Dwivedy Nasta S; Nagle SJ; Barta SK; Khan N; Filicko-O'Hara J; Gaballa S; Strelec L; Chong E; Mitnick S; Waite TS; King C; Ballard H; Youngman M; Gerson J; Plastaras JP; Maity A; Bogusz AM; Hung SS; Nakamura H; Nejati R; Steidl C; Lim M; Ruella M; Schuster SJ
    Haematologica; 2021 Jun; 106(6):1705-1713. PubMed ID: 32414850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful Treatment of an Aggressive Adult T-cell Leukemia/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy.
    Baba Y; Sakai H; Kabasawa N; Harada H
    Intern Med; 2023 Feb; 62(4):613-616. PubMed ID: 35871596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany.
    Kambhampati S; Shumilov E; Saumoy M; Herrera AF; Tilly H; Lenz G; Thiruvengadam NR
    Br J Haematol; 2023 Aug; 202(4):771-775. PubMed ID: 37188351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.
    Huntington SF; von Keudell G; Davidoff AJ; Gross CP; Prasad SA
    J Clin Oncol; 2018 Oct; 36(33):JCO1800122. PubMed ID: 30285558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.
    Hui L; von Keudell G; Wang R; Zeidan AM; Gore SD; Ma X; Davidoff AJ; Huntington SF
    Cancer; 2017 Oct; 123(19):3763-3771. PubMed ID: 28640385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China.
    Xie S; Sheng Y; Chuang LH; Wu J
    Health Econ Rev; 2024 Jun; 14(1):38. PubMed ID: 38842725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
    Izutsu K; Ogura M; Tobinai K; Hatake K; Sakamoto S; Nishimura M; Hoshino M
    Int J Hematol; 2021 Mar; 113(3):404-412. PubMed ID: 33392974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brentuximab vedotin in T-cell lymphoma.
    Van Der Weyden C; Dickinson M; Whisstock J; Prince HM
    Expert Rev Hematol; 2019 Jan; 12(1):5-19. PubMed ID: 30526166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma.
    Chen R; Allibone S; Bartlett NL; Brice P; Chen A; Pose K; Rich L; Bonthapally V; Garfin PM; Fanale M
    Onco Targets Ther; 2016; 9():2027-34. PubMed ID: 27103829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
    Tilly H; Morschhauser F; Sehn LH; Friedberg JW; Trněný M; Sharman JP; Herbaux C; Burke JM; Matasar M; Rai S; Izutsu K; Mehta-Shah N; Oberic L; Chauchet A; Jurczak W; Song Y; Greil R; Mykhalska L; Bergua-Burgués JM; Cheung MC; Pinto A; Shin HJ; Hapgood G; Munhoz E; Abrisqueta P; Gau JP; Hirata J; Jiang Y; Yan M; Lee C; Flowers CR; Salles G
    N Engl J Med; 2022 Jan; 386(4):351-363. PubMed ID: 34904799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse.
    Nguyen CN; Iyer SP; Miranda RN; Torres-Cabala CA; Curry JL; Fang P; Thomas VD; Huen AO
    JAAD Case Rep; 2021 Nov; 17():34-37. PubMed ID: 34692965
    [No Abstract]   [Full Text] [Related]  

  • 38. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
    Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
    Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy.
    Mallipudi RM; Alquran L; Shenoy VA; Leslie LA; Conti JA
    Case Rep Oncol Med; 2019; 2019():4121234. PubMed ID: 31110830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stainthorpe A; Fleeman N; Houten R; Chaplin M; Boland A; Beale S; Dundar Y; McEntee J; Syndikus I
    Pharmacoecon Open; 2020 Dec; 4(4):563-574. PubMed ID: 32207075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.